RHHVF - Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation | Benzinga
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.
The study met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant and clinically meaningful ...